Clinical Analysis of Resemblance and Dissimilarities of Glucagon-like Peptide-1 Receptor Agonists: Therapeutic Approach Towards the Management of Diabetes Mellitus

One of the classes of injective antidiabetic agents includes Glucagon-like peptide-1 receptor agonists (GLP-1RA) which ameliorate glycemia and numerous atherosclerosis-related factors in individuals prone to Type 2 diabetes mellitus (T2-DM) disorder. The review paper targeted the role of GLP-1RA in managing DM. The literature published during the last decades in several data-based searches (PubMed, Scopus, ScienceDirect) was reviewed and compiled the therapeutic uses of GLP-1 RA in the management of DM. In this review, we have discussed GLP-1RA and its role in the management of diabetes mellitus. Disrupted homeostasis marks insulin resistance and β-cell deterioration as two major indications of T2-DM. β-cells failure (~80% of functioning of β-cell) and insulin resistance in the liver and muscles are primarily susceptive to physiological defects. GLP-1RAs if administered for a prolonged period also cause a loss in weight through the activation of receptors of GLP-1 found in hypothalamic satiety centers which control appetite and decrease intake of calories. They not only assist in controlling blood glucose but also improve β- cell function and post–diabetic conditions namely hyperlipidemia, obesity, and hypertension. It was concluded that GLP-1RA has a new therapeutic approach to the management of DM. Hence, GLP-1RA provides distinctive and innovative evolution for the treatment of T2-DM.